The rapid growth of new drugs cannot hide the fatigue of medical devices: the growth of medical devices is slowing down, serving as a drag on Johnson & Johnson's impressive Q2 financial report.

According to the Smart Finance APP, due to the strong growth of sales of drugs for treating cancer, inflammatory diseases, and treatment-resistant depression, Johnson & Johnson (JNJ.US) exceeded expectations in the second quarter. The financial report shows that Johnson & Johnson's Q2 revenue reached $25.31 billion, a year-on-year increase of 6.6%, exceeding expectations by $2.5 billion; non-GAAP earnings per share were $2.90, exceeding expectations by $0.05.